RARA CRAFT DATABASE for FDA Medical Devices
510(k)K251218

FDA DEVICE FACTS

SafeBeat Rx App

SafeBeat Rx, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

AI/ML
DECISION DATEFebruary 6, 2026PRODUCT CODEDQKCLINICAL AREACardiology

Indications for use

The SafeBeat Rx App analyzes ECG data recorded in compatible formats. This ECG signal may originate from a full 12-lead ECG or a reduced lead set ECG. The device provides ECG signal processing and provisional analysis , including interval measurements (QT interval, QTc, ORS duration , heart rate, and RR interval), along with visible display of ORS onset (Q-start), R-peak, and ORS offset (S-end) . The SafeBeat Rx App can electronically interface with, and perform analysis of, data transferred from other computer-based ECG systems , such as an ECG management system . The SafeBeat Rx App does not provide real-time ECG display , continuous monitoring , or alarm functions . The device is not for use in life-supporting or sustaining systems or ECG monitor and alarm devices. The SafeBeat Rx App ECG analysis is intended for adult patient populations (18 years and older ). SafeBeat Rx App provisional ECG analysis is not intended to be the sole means of diagnosis. The SafeBea Rx App is not validated for use in lead I alone. The SafeBeat Rx App is intended to be used on an advisory basis only by qualified healthcare personnel to evaluate provisional ECG data. ECG data should be reviewed in conjunction with the patient's clinical history, symptoms, and/or other diagnostic tests, and the professional clinical judgement of the qualified healthcare provider . The SafeBeat Rx App can be used in a professional healthcare environment such as a hospital , clinic or similarly equipped facility. The SafeBeat Rx App has an optional long term monitoring workflow intended for monitoring and evaluating a patient's home acquired ECG. The software workflow that is intended for use in the professional healthcare environment should not be used in the home environment to adjust QT prolonQinQ medications as is contraindicated for applicable druQs.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 22, 2026